Melissa B. Epperly

Insider Reports History

Identity 1 identity field
Location
Philadelphia, PA
SEC filing record 1 source field
SEC signature
By: /s/ Jo Chen, as Attorney-in-Fact for Melissa B. Epperly
SEC evidence 1 source field
Transaction evidence
Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Melissa B. Epperly

Form 4 holding Chief Financial Officer

Zentalis Pharmaceuticals, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
75,000
Estimated value
Report date
01 Feb 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Kinnate Biopharma Inc.

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
03 Apr 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Melissa B. Epperly

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .